[lbeltrame]

> - A serology study is conducted at the moment in Geneva, it seems that our estimates of seroprevalence (Fig. 5: only 3% country wide by April 24) are consistent with the study (Appendix Fig. 7). We were very happy of that.

What about individual regions? I ask because most of the dynamics I've seen originate around hotspots, and thus it may be interesting to see how individual regions were affected (because it may drive different responses).

E.g., the Spain seroprevalence study said 5% country wide. But the estimates per regions can be as up to 3 times that (Madrid itself is ~11%).

[wosk]

True. We estimated seroprevalence for cantons ("states" of Switzerland, ranging from small to very small). As you says, there is some quite some difference (Fig. 5): Tessin (border with Italia) and French-speaking cantons (Geneva, Vaud) have a much higher seroprevalence than the rest of the country.

The same has been found by other groups on France.

[lbeltrame]

I think it's quite important, because it may drive local public policy depending on the results: especially if one considers the models of "shield immunity" (discussed at length in one Nature publication a few weeks ago) in reducing transmission (no government has taken interest in them, AFAICS).